Scott G. Franzblau
Director, Institute for Tuberculosis Research
Albert Schatz Professor, College of Pharmacy - Pharmaceutical Sciences
Contact
Office Phone:
Email:
Related Sites:
About Heading link
Research Interests:
1) New drug discovery for tuberculosis, non-tuberculous mycobacteria, Lyme Disease and ESKAPE pathogens
2) Antimicrobial assay development
3) Isolation of novel minor bioactive secondary metabolites
Teaching and Supervision Heading link
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PSCI Ph.D. Thesis Research (PSCI 599), 8/23/2021 – 12/3/2021
PHAR 506 (PHAR 506), 2/24/2021 – 2/24/2021
Undergrad Res Exp MedChem&Pcog (PMMP 300), 1/14/2019 – 5/3/2019
Spec Project Med Chem &Pcog (PMMP 390), 1/9/2017 – 4/28/2017
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Lab Tech in Pcog I (PMPG 590), 1/11/2016 – 4/29/2016
Selected Grants
Host-directed Proteolysis-Targeting Chimera (PROTAC) approach to target intracellular Mycobacterium tuberculosis"., TB Alliance., 7/15/2024 - 7/14/2026, Obligated Amount: $97142.67; Anticipated Amount: $97142.67
In Vitro Testing Of Candidate Anti-Tubercular Compounds (Master under 109178), Global Alliance for TB Drug Development., 4/1/2023 - 11/30/2025, Obligated Amount: $1143995.36; Anticipated Amount: $1143995.36
To identify natural product molecules with potential activity against tuberculosis, National Institutes of Health (National Cancer Institute)., 1/6/2023 - 1/5/2025, No Obligated Amount Set; No Anticipated Amount Set
Design, Syntheses and Studies of Novel Antituberculosis Agents, University of Notre Dame., 9/1/2021 - 8/31/2025, Obligated Amount: $371596; Anticipated Amount: $371596
Provide heat inactivated cell suspensions of four mycobacterial strains to EpicGenetics, EpicGenetics., 8/1/2021 - 1/31/2022, Obligated Amount: $3980; Anticipated Amount: $3980
In Vitro testing of candidate anti-tubercular compounds (Master under 109178), Global Alliance for TB Drug Development., 4/1/2021 - 3/31/2024, Obligated Amount: $758690; Anticipated Amount: $758690
★ Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb, Global Alliance for TB Drug Development., 4/1/2019 - 3/31/2024, Obligated Amount: $8489541; Anticipated Amount: $8489541
A new paradigm for the creation and mining of microbial libraries for drug discovery, National Institutes of Health (National Institute of General Medical Sciences)., 8/10/2018 - 7/31/2023, Obligated Amount: $2069671; Anticipated Amount: $2069671
★ In Vitro Testing of Candidate Anti-Tubercular Compounds (MASTER under 109178), Global Alliance for TB Drug Development., 10/1/2005 - 3/31/2024, Obligated Amount: $10312702; Anticipated Amount: $10312702
Selected Publications
Tan, Jin Yi, Augustinović, Mario, Omar, Ashraf M, Lourenzon, Vitor B, Krull, Nyssa, Lopez, Xochitl, Khin, Manead, Shetye, Gauri, Nguyen, Duc, Qader, Mallique, Nugent, Angela C, Mpofu, Enock, Williams, Camarria, Rodriguez, Jonathon, Burdette, Joanna E, Cho, Sanghyun, Franzblau, Scott G, Eustáquio, Alessandra S, Zhang, Qibin, Murphy, Brian T. (2024). Discovery of New Cyclic Lipodepsipeptide Orfamide N via Partnership with Middle School Students from the Boys and Girls Club. ACS Omega, 9, (44), 44749-44759. doi:10.1021/acsomega.4c07459.
González-González, Alonzo, Sánchez-Sánchez, Oscar, Wan, Baojie, Franzblau, Scott, Palos, Isidro, Espinoza-Hicks, José C, Moreno-Rodríguez, Adriana, Martínez-Vázquez, Ana Verónica, Lara-Ramírez, Edgar E, Ortiz-Pérez, Eyra, Paz-González, Alma D, Rivera, Gildardo. (2024). Expanding the chemical space of ester of quinoxaline-7-carboxylate 1,4-di- N -oxide derivatives as potential antitubercular agents. RSC Medicinal Chemistry, 15, (8), 2785-2791. doi:10.1039/d4md00221k.
Kumar, Boddupalli Venkata Siva, Khetmalis, Yogesh Mahadu, Chaitanya, Kosana Sai, Chandu, Ala, Shetye, Gauri, Ma, Rui, Murugesan, Sankaranarayanan, Franzblau, Scott G, Sekhar, Kondapalli Venkata Gowri Chandra. (2024). Design, synthesis and biological evaluation of novel pyrido-[2,3-d]-pyrimidin-2-amine analogues as antimycobacterial agents. Journal of Molecular Structure, 1303, 137600. doi:10.1016/j.molstruc.2024.137600.
Wang, Weihong, Lee, JunI, Roh, Eun, Shetye, Gauri, Cao, Jin, McAlpine, James, Pauli, Guido, Franzblau, Scott, Vu, Thi Hanh Nguyen, Quach, Ngoc Tung, Oh, Eunseok, Park, Kyu-Hyung, Park, Chanyoon, Cho, Youbin, Jang, Hyeseon, Han, SongJoo, Kim, Hiyoung, Cho, Sanghyun, Phi, Quyet-Tien, Kang, Heonjoong. (2024). Cavomycins A–C, Linear Oligomer Depsipeptides from an Annelid-Associated Streptomyces cavourensis. Journal of Natural Products, 87, (4), 976-983. doi:10.1021/acs.jnatprod.3c01275.
Nandikolla, Adinarayana, Khetmalis, Yogesh Mahadu, Venkata Siva Kumar, Boddupalli, Chandu, Ala, Karan Kumar, Banoth, Shetye, Gauri, Ma, Rui, Murugesan, Sankaranarayanan, Franzblau, Scott G, Chandra Sekhar, Kondapalli Venkata Gowri. (2023). Design, synthesis and biological evaluation of phenanthridine amide and 1,2,3-triazole analogues against Mycobacterium tuberculosis. RSC Medicinal Chemistry, 14, (8), 1549-1561. doi:10.1039/d3md00115f.
Lee, Jung-Ho, Ma, Rui, Nguyen, Linh, Khan, Shahebraj, Qader, Mallique, Mpofu, Enock, Shetye, Gauri, Krull, Nyssa K, Augustinović, Mario, Omarsdottir, Sesselja, Cho, Sanghyun, Franzblau, Scott G, Murphy, Brian T. (2023). Discovery of a New Antibiotic Demethoxytetronasin Using a Dual-Sided Agar Plate Assay (DAPA). ACS Infectious Diseases, 9, (8), 1593-1601. doi:10.1021/acsinfecdis.3c00171.
Chhetri, Bhuwan Khatri, Bhanushali, Riya, Liang, Yifan, Cepeda, Marisa R, Niradininoco, Adi Kula, Soapi, Katy, Wan, Baojie, Qader, Mallique, Franzblau, Scott G, Kubanek, Julia. (2023). Isolation and Characterization of Anti-Mycobacterial Natural Products from a Petrosia sp. Marine Sponge. Journal of Natural Products, 86, (3), 574-581. doi:10.1021/acs.jnatprod.2c01003.
Zhang, Jidong, Lair, Christine, Roubert, Christine, Amaning, Kwame, Barrio, María Belén, Benedetti, Yannick, Cui, Zhicheng, Xing, Zhongliang, Li, Xiaojun, Franzblau, Scott G, Baurin, Nicolas, Bordon-Pallier, Florence, Cantalloube, Cathy, Sans, Stephanie, Silve, Sandra, Blanc, Isabelle, Fraisse, Laurent, Rak, Alexey, Jenner, Lasse B, Yusupova, Gulnara, Yusupov, Marat, Zhang, Junjie, Kaneko, Takushi, Yang, TJ, Fotouhi, Nader, Nuermberger, Eric, Tyagi, Sandeep, Betoudji, Fabrice, Upton, Anna, Sacchettini, James C, Lagrange, Sophie. (2023). Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents. Cell, 186, (5), 1013-1025.e24. doi:10.1016/j.cell.2023.01.043.
Kamat, Vinuta, Poojary, Boja, Puthran, Divyaraj, Das, Vishwa B, Kumar, Banoth K, Sankaranarayan, Murugesan, Shetye, Gauri, Ma, Rui, Franzblau, Scott G, Nayak, Suresh P. (2023). Synthesis, antimycobacterial, cytotoxicity, anti‐inflammatory, in silico studies and molecular dynamics of pyrazole‐embedded thiazolidin‐4‐one hybrids. Archiv der Pharmazie, 356, (3), e2200444. doi:10.1002/ardp.202200444.
Education
Degrees:
B.S, Rutgers University, United States, 1976
MS, University of Arizona, United States, 1978
PhD, University of Arizona, United States, 1982
Postgraduate Training:
Postgraduate, Kurume University, Japan, 1984